Valmark Advisers Inc. Decreases Stock Position in Pfizer Inc. $PFE

Valmark Advisers Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,227 shares of the biopharmaceutical company’s stock after selling 990 shares during the quarter. Valmark Advisers Inc.’s holdings in Pfizer were worth $951,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PFE. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Pfizer by 69.0% in the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock worth $1,600,000 after buying an additional 25,785 shares during the last quarter. Integrated Advisors Network LLC increased its holdings in shares of Pfizer by 20.9% in the 1st quarter. Integrated Advisors Network LLC now owns 69,834 shares of the biopharmaceutical company’s stock worth $1,770,000 after buying an additional 12,064 shares during the last quarter. Finally, Donaldson Capital Management LLC increased its holdings in shares of Pfizer by 8.6% in the 1st quarter. Donaldson Capital Management LLC now owns 38,772 shares of the biopharmaceutical company’s stock worth $982,000 after buying an additional 3,078 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Price Performance

Shares of PFE stock opened at $25.22 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $143.39 billion, a P/E ratio of 13.41, a P/E/G ratio of 0.84 and a beta of 0.55. The company’s 50-day simple moving average is $24.83 and its two-hundred day simple moving average is $24.14. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.08.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.